Identification and quantitation of a new cathinone designer drug PV9 in an “aroma liquid” product, antemortem whole blood and urine specimens, and a postmortem whole blood specimen in a fatal poisoning case

2014 ◽  
Vol 32 (2) ◽  
pp. 243-250 ◽  
Author(s):  
Koutaro Hasegawa ◽  
Amin Wurita ◽  
Kayoko Minakata ◽  
Kunio Gonmori ◽  
Hideki Nozawa ◽  
...  
2013 ◽  
Vol 31 (2) ◽  
pp. 328-332 ◽  
Author(s):  
Takeshi Saito ◽  
Akira Namera ◽  
Motoki Osawa ◽  
Hiromichi Aoki ◽  
Sadaki Inokuchi

1985 ◽  
Vol 31 (2) ◽  
pp. 308-308
Author(s):  
Ronald H Ng ◽  
Mani Menon ◽  
Jack H Ladenson

Abstract Vol. 30 p 468: In line 7, left column, HCl should be 12 mol/L. p 536: In Figs. 4 and 5, change the unit on the ordinates to "%." Change the ordinate numbers on Fig. 4 from 0, 20, 40, 60, 80, and 100 to 0, 5, 10, 15, 20, 25. On Fig. 5, change the ordinate number from 120 to 30. p 725: In line 8, right column, change "logarithmic probability," to "probit." In Figs. 2 and 3, replace the terms "log 10" and "double log" by "probit" and "simple log," respectively. p 729: Insert "γ" in the empty space on line 23, right-hand column, so the expression reads "100(1 – γ)%." pp 856–7: Exchange the legends for Figures 2 and 3. p 1111: Units in the left-hand Table should be "µg/L," not "g/L." p 1260: In the first column, just under equation 2, delete "β" and insert the words "for a." p 1294: In paragraph three, line 6, for "blunted" read "blunt." p 1353: Transpose Figures 2 and 3 over the (unchanged) legends. 0.53 1.02 2.71 5.0 p 1364: The sixth line of data, columns 2–4 should read "176.4 ± 43," "470 ± 198," and "0.5." The final line of data, columns 2–4, should read "1.95 ± 0.47," "5.05 ± 2.12," and "0.4," and, under "Range" the following should be inserted at the bottom of the column: 0.4–0.7 0.2–0.8 0.1–0.7. p 1365: The data in columns 2 and 4, and some in column 3, of Table 3 should read: See table in the PDF file p 1429: The middle column, next to last paragraph, should read: "Hb 27 g/L" and "leukocytes 186 x 109/L." p 1812: Column 1, fifth line of text: change "decreasing" to "increasing." p 1813: Column 2, x refers to whole blood rather than plasma, y to plasma.


2004 ◽  
Vol 139 (2-3) ◽  
pp. 191-194 ◽  
Author(s):  
G. Boatto ◽  
M. Nieddu ◽  
A. Carta ◽  
A. Pau ◽  
S. Lorenzoni ◽  
...  

1969 ◽  
Vol 15 (7) ◽  
pp. 566-574 ◽  
Author(s):  
R O Farrelly ◽  
J Pybus

Abstract An extraction method for the estimation of lead in red cells is given. The method avoids both acid digestion and/or protein precipitation. It is extremely simple and reliable, and can easily be performed by technicians. A technical error of 4.5 v.g lead per 100 ml of red cells has been obtained. The use of red cells instead of whole blood provides a more accurate measure of exposure to lead as the lead is concen¬trated within the red cells. Normal and toxic ranges are given. As it is frequently required to monitor the lead excretion of patients receiving chelates for therapy, a method for the analysis of urine specimens from patients on this therapy is given.


2016 ◽  
Vol 267 ◽  
pp. e6-e9 ◽  
Author(s):  
Kosei Yonemitsu ◽  
Ako Sasao ◽  
Satoko Mishima ◽  
Yuki Ohtsu ◽  
Yoko Nishitani

2014 ◽  
Vol 33 (1) ◽  
pp. 141-147 ◽  
Author(s):  
Koutaro Hasegawa ◽  
Amin Wurita ◽  
Kayoko Minakata ◽  
Kunio Gonmori ◽  
Hideki Nozawa ◽  
...  

1982 ◽  
Vol 28 (3) ◽  
pp. 499-502
Author(s):  
C T Brooks ◽  
J B Copas ◽  
R W Oliver

Abstract We present and discuss the results of a statistical study of a set of radioimmunoassay data obtained from parallel determinations of the total estriol content of samples of serum and plasma prepared from 98 specimens of whole blood, taken from pregnant woman. Estriol concentrations in the serum exceed by an average of 7% the values found for the plasma prepared from the same whole-blood specimen. The clinical significance of this analytical finding is discussed, and we conclude with the recommendation that serum is the fluid of choice for this assay.


Author(s):  
Ariane Wohlfarth ◽  
Karl B. Scheidweiler ◽  
Marisol Castaneto ◽  
Adarsh S. Gandhi ◽  
Nathalie A. Desrosiers ◽  
...  

AbstractIdentifying synthetic cannabinoid designer drug abuse challenges toxicologists and drug testing programs. The best analytical approach for reliably documenting intake of emerging synthetic cannabinoids is unknown. Primarily metabolites are found in urine, but optimal metabolite targets remain unknown, and definitive identification is complicated by converging metabolic pathways.We screened 20,017 US military urine specimens collected from service members worldwide for synthetic cannabinoids between July 2011 and June 2012. We confirmed 1432 presumptive positive and 1069 presumptive negative specimens by qualitative liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis including 29 biomarkers for JWH-018, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-250, RCS-4, AM2201 and MAM2201. Specimen preparation included enzyme hydrolysis and acetonitrile precipitation prior to LC-MS/MS analysis. We evaluated individual synthetic cannabinoid metabolite detection rates, prevalence, temporal patterns and suitable targets for analytical procedures.Prevalence was 1.4% with 290 confirmed positive specimens, 92% JWH-018, 54% AM2201 and 39% JWH-122 metabolites. JWH-073, JWH-210 and JWH-250 also were identified in 37%, 4% and 8% of specimens, respectively. The United States Army Criminal Investigation Command seizure pattern for synthetic cannabinoid compounds matched our urine specimen results over the time frame of the study. Apart from one exception (AM2201), no parent compounds were observed.Hydroxyalkyl metabolites accounted for most confirmed positive tests, and in many cases, two metabolites were identified, increasing confidence in the results, and improving detection rates. These data also emphasize the need for new designer drug metabolism studies to provide relevant targets for synthetic cannabinoid identification.


Sign in / Sign up

Export Citation Format

Share Document